Company news
Paradigm Biopharmaceuticals Ltd. (ASX:PAR) news
Paradigm Biopharmaceuticals Ltd. news releases on 6ix. Latest, Feb 7, 2024: Paradigm Receives $7.36m R&D Tax Incentive Refund
Press releases — page 2
Paradigm Receives $7.36m R&D Tax Incentive Refund
February 6, 2024
Security Class Reinstatement to Quotation PARO
November 27, 2023
Successful completion of Retail Entitlement Offer
November 23, 2023
Security Class Suspension from Quotation PARO
November 20, 2023
Paradigm to Recommence Trading
October 31, 2023
Replacement Entitlement Offer and Placement Prospectus
October 31, 2023
PAR Successful Placement and Fully Underwritten ANREO
October 31, 2023
Entitlement Offer and Placement Prospectus
October 29, 2023
Investor Presentation - $30m Capital Raise
October 29, 2023
Paradigm Launches $30M Capital Raising
October 29, 2023
iPPS Increases Cartilage Thickness in Phase 2 Trial
October 17, 2023
iPPS SIGNIFICANT OA PAIN REDUCTION AT 12 MONTHS
October 9, 2023
2023 Annual Report and Appendix 4E
August 25, 2023
PAR Reports Phase 3 Clinical Trial Update
July 3, 2023
Primary and Secondary endpoints met in MPS I Trial
June 6, 2023
iPPS shows 3-year equivalent durability in OA Canine Study
May 31, 2023
iPPS Demonstrates Multiple DMOAD Signals in Phase 2 Study
April 3, 2023
Phase 3 OA Trial to Proceed after Formal Safety Review
December 28, 2022
PAR Receives Allowance for Key US Patent
December 11, 2022
Paradigm CEO steps down & Appointment of MD
November 21, 2022
Paradigm Receives $7.4m R&D Tax Incentive Refund
November 18, 2022
Paradigm Doses First UK Participant in Phase 3 Trial
October 25, 2022
PAR Reports Successful Primary Endpoint in Phase 2 Trial
October 3, 2022
Successful MPSVI Safety Review and PARA OA 008 Update
September 25, 2022
Successful Completion of Entitlement Offer
September 12, 2022
2022 Annual Report and Appendix 4E
August 25, 2022
PAR Non-Renounceable Rights Issue Offer Booklet
August 21, 2022
Investor Presentation - $66m Capital Raise
August 14, 2022
Paradigm Launches $66M Capital Raising
August 14, 2022
Paradigm provides MPS Clinical Program update
August 7, 2022
Quarterly Update and Appendix 4C - quarterly
July 27, 2022
Paradigm Partners with NFL Alumni Health for OA Program
July 13, 2022
Paradigm reports global progress in phase 3 study
July 5, 2022
100% Recruitment in Synovial Fluid Biomarker Trial
June 30, 2022
Paradigm Reports Australian Patent Acceptance
June 29, 2022
Paradigm Receives $8.2m R&D Tax Incentive Refund
June 6, 2022
Paradigm Appoints Experienced US-Based CEO
May 29, 2022
Paradigm Doses First US Subjects under Phase 3 trial
April 28, 2022
FDA Grants Paradigm Fast Track Designation For OA
April 12, 2022
Clarification of recent analyst report on Patent Protection
March 9, 2022
S&P DJI Announces March 2022 Quarterly Rebalance
March 4, 2022
Paradigm 1HY22 Key Activity Highlights
February 23, 2022
PARADIGM TREATS FIRST SUBJECTS IN PHASE 3 TRIAL OF ZILOSUL
January 12, 2022
PAR REPORTS POSTIVE TOPLINE RESULTS IN HEART FAILURE MODEL
December 16, 2021
Preliminary Results from Phase 2 MPS I Study
November 22, 2021
Paradigm CEO Paul Rennie to transition to Non-Exec Chairman
November 21, 2021
PARADIGM CLEARED FOR PHASE 3 TRIAL BY US FDA
November 2, 2021
Phase 2 Synovial Fluid Biomarker Study Update
October 25, 2021
POSITIVE TOP-LINE RESULTS FROM PRECLINICAL STUDY IN ARDS
October 12, 2021
FIRST MPS-VI PATIENT DOSED UNDER PHASE 2 TRIAL IN BRAZIL
September 30, 2021